NASDAQ:IDXX - IDEXX Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $474.60
  • Forecasted Upside: -21.04 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -3.15 (-0.52%)
1 month | 3 months | 12 months
Get New IDEXX Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDXX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDXX

Average Price Target: $474.60
▼ -21.04% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for IDEXX Laboratories in the last 3 months. The average price target is $474.60, with a high forecast of $616.00 and a low forecast of $375.00. The average price target represents a -21.04% upside from the last price of $601.05.


The current consensus among 5 polled investment analysts is to buy stock in IDEXX Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2021BarclaysBoost Price TargetOverweight$600.00 ➝ $616.00Low
2/17/2021BarclaysInitiated CoverageOverweight$600.00Low
1/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight$570.00Low
8/17/2020Credit Suisse GroupBoost Price TargetOutperform$415.00 ➝ $422.00Low
8/4/2020Credit Suisse GroupBoost Price TargetOutperform$300.00 ➝ $415.00Low
7/30/2020Stifel NicolausBoost Price TargetBuy$280.00 ➝ $375.00Low
7/20/2020Bank of AmericaBoost Price TargetBuy$300.00 ➝ $390.00Medium
5/1/2020Stifel NicolausBoost Price TargetBuy$266.00 ➝ $280.00Medium
11/1/2019GuggenheimSet Price TargetBuy$310.00Low
9/9/2019The Goldman Sachs GroupInitiated CoverageNeutral$277.00High
8/16/2019Credit Suisse GroupBoost Price TargetOutperform$282.00 ➝ $293.00Low
8/2/2019Canaccord GenuityReiterated RatingBuy$285.00Low
7/22/2019Stifel NicolausBoost Price TargetBuy$255.00 ➝ $295.00Low
7/1/2019Canaccord GenuityReiterated RatingBuy$280.00Low
6/21/2019Bank of AmericaSet Price TargetBuy$300.00Low
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$276.00Medium
5/2/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$255.00 ➝ $260.00Low
3/26/2019Canaccord GenuityLower Price TargetBuy$255.00 ➝ $254.00Low
11/5/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$270.00 ➝ $250.00Low
11/2/2018Bank of AmericaLower Price TargetBuy ➝ Buy$275.00 ➝ $235.00Low
8/17/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$255.00 ➝ $259.00Low
8/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$236.00Medium
7/10/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$225.00 ➝ $260.00High
6/21/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$228.00 ➝ $231.00Low
6/1/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$209.00 ➝ $228.00High
5/7/2018Canaccord GenuityReiterated RatingBuy ➝ Positive$215.00High
5/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$215.00 ➝ $225.00High
2/2/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$200.00 ➝ $220.00High
2/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$211.00High
1/29/2018Canaccord GenuityReiterated RatingBuy$210.00Low
1/16/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$200.00High
12/8/2017AegisReiterated RatingSellLow
10/24/2017Stifel NicolausReiterated RatingBuy$185.00N/A
10/6/2017Canaccord GenuityReiterated RatingBuy$180.00N/A
8/23/2017Bank of AmericaUpgradeNeutral ➝ Buy$175.00Low
8/22/2017Canaccord GenuityReiterated RatingBuy$180.00Low
8/21/2017Stifel NicolausReiterated RatingBuy$185.00Low
8/2/2017Stifel NicolausReiterated RatingBuy$185.00High
7/28/2017CL KingUpgradeNeutral ➝ Buy$200.00Medium
7/14/2017Stifel NicolausReiterated RatingBuy$185.00Low
6/13/2017Canaccord GenuityReiterated RatingBuy$180.00Low
5/31/2017AegisInitiated CoverageSell$118.00Low
5/1/2017Stifel NicolausBoost Price TargetBuy$150.00 ➝ $185.00Low
4/28/2017Canaccord GenuityReiterated RatingBuy$165.00 ➝ $180.00Low
2/14/2017Canaccord GenuitySet Price TargetBuy$145.00N/A
2/3/2017Feltl & Co.DowngradeHold ➝ SellN/A
1/31/2017Canaccord GenuitySet Price TargetBuy$125.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$125.00N/A
10/15/2016Canaccord GenuitySet Price TargetBuy$125.00N/A
9/29/2016Bank of AmericaReiterated RatingNeutralN/A
8/22/2016Canaccord GenuityReiterated RatingBuy$120.00N/A
8/16/2016Stifel NicolausBoost Price TargetBuy$120.00 ➝ $125.00N/A
8/3/2016Stifel NicolausReiterated RatingBuy$92.00 ➝ $120.00N/A
8/3/2016Northcoast ResearchUpgradeSell ➝ NeutralN/A
8/2/2016Canaccord GenuityReiterated RatingBuyN/A
7/20/2016Canaccord GenuityBoost Price TargetBuy$90.00 ➝ $98.00N/A
(Data available from 6/18/2016 forward)
IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $601.05
Low: $599.94
High: $609.22

50 Day Range

MA: $548.41
Low: $506.43
High: $604.20

52 Week Range

Now: $601.05
Low: $310.10
High: $609.22


722,275 shs

Average Volume

420,046 shs

Market Capitalization

$51.26 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of IDEXX Laboratories?

The following Wall Street research analysts have issued reports on IDEXX Laboratories in the last year: Bank of America Co., Barclays PLC, Credit Suisse Group AG, JPMorgan Chase & Co., Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for IDXX.

What is the current price target for IDEXX Laboratories?

5 Wall Street analysts have set twelve-month price targets for IDEXX Laboratories in the last year. Their average twelve-month price target is $474.60, suggesting a possible downside of 21.0%. Barclays PLC has the highest price target set, predicting IDXX will reach $616.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $375.00 for IDEXX Laboratories in the next year.
View the latest price targets for IDXX.

What is the current consensus analyst rating for IDEXX Laboratories?

IDEXX Laboratories currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IDXX will outperform the market and that investors should add to their positions of IDEXX Laboratories.
View the latest ratings for IDXX.

What other companies compete with IDEXX Laboratories?

How do I contact IDEXX Laboratories' investor relations team?

IDEXX Laboratories' physical mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company's listed phone number is (207) 556-0300 and its investor relations email address is [email protected] The official website for IDEXX Laboratories is